Respiratory failure in confirmed synthetic cannabinoid overdose
- PMID: 34499005
- PMCID: PMC9875316
- DOI: 10.1080/15563650.2021.1975734
Respiratory failure in confirmed synthetic cannabinoid overdose
Abstract
Context: Synthetic cannabinoids (SCs) are a structurally heterogenous synthetic class of drugs of abuse. The objective was to describe the incidence of acute respiratory failure in Emergency Department (ED) patients with confirmed SC exposure, and to investigate the association between SC overdose with respiratory failure compared to non-SC overdose.
Methods: This was an observational cohort of ED patients ≥18 years with suspected cannabinoid overdose between 2015 and 2020 at two tertiary-care hospitals. Patient serum was analyzed via liquid chromatography/quadrupole time-of-flight mass spectrometry using a library with >800 drugs including novel psychoactive substances. The primary outcome was acute respiratory failure.
Discussion: Of 83 patients with suspected cannabinoid overdose, there were 29 confirmed SC overdoses: 5 F-MDMB-PICA (n = 18) and its metabolite 5OH-MDMB-PICA (n = 16), ADB-FUBINACA (n = 4), AB-CHIMINACA (n = 4), AB-FUBINACA (n = 1), AB-PINACA (n = 1), MDMB-4en-PINACA (n = 1), and 4 F-MDMB-BINACA (n = 1). Overall, incidence of acute respiratory failure was 31.3% (95%CI 21.6-42.4). Compared to non-SC overdose, confirmed SC overdose was significantly associated with respiratory failure (25.0% SC vs. 4.2% non-SC, p = 0.05).
Conclusion: This study demonstrates that SCs are associated with respiratory failure. Since respiratory depression is a potentially lethal adverse effect of SC overdose, future research is warranted.
Keywords: SCRAs; Synthetic cannabinoids; naloxone; respiratory failure; synthetic cannabinoid receptor agonists.
Conflict of interest statement
Disclosure statement
The authors declare no commercial conflicts of interest.
Figures
References
-
- Alves VL, Gonçalves JL, Aguiar J, et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359–382. - PubMed
-
- Hermanns-Clausen M, Müller D, Kithinji J, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol (Phila)). 2018;56(6):404–411. - PubMed
-
- Jinwala FN, Gupta M. Synthetic cannabis and respiratory depression. J Child Adolesc Psychopharmacol. 2012;22(6):459–462. - PubMed
-
- Richards JR, Schandera V, Elder JW. Treatment of acute cannabinoid overdose with naloxone infusion. Toxicology Communications. 2017;1(1):29–33.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical